机构:[1]Cleveland Clin, Cleveland, OH 44106 USA[2]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China四川大学华西医院[3]Univ Texas MD Anderson Hosp, Houston, TX USA[4]Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia[5]Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA[6]Erasmus MC, Rotterdam, Netherlands[7]Beijing Canc Hosp, Beijing, Peoples R China[8]Guys & St Thomas Hosp, London, England[9]Hop Nord Marseille, Marseille, France[10]Indiana Univ, Med Ctr, Indianapolis, IN USA[11]Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA[12]Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA[13]Helsinki Univ Hosp, Helsinki, Finland[14]Univ Med Ctr Utrecht, Utrecht, Netherlands[15]Shanghai Chest Hosp, Shanghai, Peoples R China[16]Univ Buenos Aires, Hosp Clin, Buenos Aires, DF, Argentina[17]Univ Sao Paulo, Sch Med, Sao Paulo, Brazil[18]Royal Marsden NHS Fdn Trust, London, England[19]Univ Alabama Birmingham, Sect Thorac Surg, Birmingham, AL USA[20]Hosp Univ Mar, Barcelona, Spain[21]Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England[22]Univ Cape Town, Groote Schuur Hosp, Cape Town, South Africa[23]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院胸三科临床科室[24]Mayo Clin, Rochester, MN USA[25]Univ Hong Kong, Med Ctr, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China[26]Univ Rochester, Rochester, NY USA[27]Toronto Gen Hosp, Toronto, ON, Canada[28]Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA[29]Univ Montreal, Montreal, PQ, Canada[30]Med Univ South Carolina, Charleston, SC USA[31]Oregon Hlth & Sci Univ, Portland, OR 97201 USA[32]Univ Ziekenhuizen Leuven, Leuven, Belgium[33]Univ Michigan, Ann Arbor, MI 48109 USA[34]Univ Miami, Miami, FL USA[35]Case Western Reserve Univ, Cleveland, OH 44106 USA
We report datasimple descriptions of patient characteristics, cancer categories, and non-risk-adjusted survivalfor patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0-2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non-risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.
Rice T. W.,Chen L. -Q.,Hofstetter W. L.,et al.Worldwide Esophageal Cancer Collaboration: pathologic staging data[J].DISEASES OF THE ESOPHAGUS.2016,29(7):724-733.doi:10.1111/dote.12520.
APA:
Rice, T. W.,Chen, L. -Q.,Hofstetter, W. L.,Smithers, B. M.,Rusch, V. W....&Blackstone, E. H..(2016).Worldwide Esophageal Cancer Collaboration: pathologic staging data.DISEASES OF THE ESOPHAGUS,29,(7)
MLA:
Rice, T. W.,et al."Worldwide Esophageal Cancer Collaboration: pathologic staging data".DISEASES OF THE ESOPHAGUS 29..7(2016):724-733